

AMENDMENTS TO THE CLAIMS

This listing of the claims replaces all prior listings and versions:

1. (canceled).
2. (withdrawn): An expression cassette comprising
a polynucleotide ~~comprising X contiguous nucleotides, wherein (i) the X contiguous~~
~~nucleotides have~~ comprising a sequence having at least 90% percent identity to the full-length of the
sequence shown in ~~Y contiguous nucleotides of SEQ ID NO:46, (ii) X equals Y, and (iii) Y is at~~
~~least 97.~~
3. (withdrawn): The expression cassette of claim 2, comprising
a polynucleotide ~~comprising X contiguous nucleotides, wherein (i) the X contiguous~~
~~nucleotides have~~ comprising a sequence having at least 90% percent identity to the full-length of the
sequence shown in ~~Y contiguous nucleotides of SEQ ID NO:47, (ii) X equals Y, and (iii) Y is at~~
~~least 144.~~
4. (withdrawn): The expression cassette of claim 3, comprising
a polynucleotide ~~comprising X contiguous nucleotides, wherein (i) the X contiguous~~
~~nucleotides have~~ comprising a sequence having at least 90% percent identity to the full-length of the
sequence shown in ~~Y contiguous nucleotides of SEQ ID NO:49 or SEQ ID NO:97, (ii) X equals Y,~~
~~and (iii) Y is at least 300.~~
- 5 to 37. (canceled).
38. (currently amended): An expression cassette comprising
a polynucleotide ~~comprising X contiguous nucleotides, wherein (i) the X contiguous~~
~~nucleotides have~~ comprising a sequence having at least 90% percent identity to the full-length
sequence of the sequence shown in ~~Y contiguous nucleotides of SEQ ID NO:119, SEQ ID NO:120;~~
~~SEQ ID NO:121; SEQ ID NO:122; SEQ ID NO:123; SEQ ID NO:124; SEQ ID NO:125; SEQ ID~~
~~NO:126; SEQ ID NO:127; SEQ ID NO:131; SEQ ID NO:132 or SEQ ID NO:133, (ii) X equals Y,~~
~~and (iii) Y is at least 60.~~
- 39 to 77. (canceled).

78. (withdrawn): A method of immunization of a subject, comprising, introducing an expression cassette composition of claim 38 ~~71~~ into said subject under conditions that are compatible with expression of said expression cassette in said subject.

79. (withdrawn): The method of claim 78, wherein said expression cassette is introduced using a gene delivery vector.

80. (withdrawn): The method of claim 79, wherein the gene delivery vector is a non-viral vector.

81. (withdrawn): The method of claim 79, wherein said gene delivery vector is a viral vector.

82. (withdrawn): The method of claim 79, wherein said gene delivery vector is selected from the group consisting of an adenoviral vector, a vaccinia viral vector, an AAV vector, a retroviral vector, a lentiviral vector and an alphaviral vector.

83. (withdrawn): The method of claim 82, wherein said gene delivery vector is a Sindbis-virus derived vector.

84. (withdrawn): The method of claim 82, wherein said gene delivery vector is a cDNA vector.

85. (withdrawn): The method of claim 82, wherein said gene delivery vector is a eukaryotic layered viral initiation system (ELVIS).

86. (withdrawn): The method of claim 79, wherein said composition delivered using a particulate carrier.

87. (withdrawn): The method of claim 79, wherein said composition is coated on a gold or tungsten particle and said coated particle is delivered to said subject using a gene gun.

88. (withdrawn): The method of claim 79, wherein said composition is encapsulated in a liposome preparation.

89. (withdrawn): The method of claim 79, wherein said subject is a mammal.
90. (withdrawn): The method of claim 89, wherein said mammal is a human.
91. (withdrawn): A method of generating an immune response in a subject, comprising:
providing an expression cassette of claim 38 ~~4~~,
expressing said polypeptide in a suitable host cell,
isolating said polypeptide, and
administering said polypeptide to the subject in an amount sufficient to elicit an immune response.
92. (withdrawn): A method of generating an immune response in a subject, comprising
introducing into cells of said subject an expression cassette of claim 38 ~~4~~, under conditions
that permit the expression of said polynucleotide and production of said polypeptide, thereby
eliciting an immunological response to said polypeptide.
93. (withdrawn): The method of claim 92, where the method further comprises co-
administration of an HIV polypeptide.
94. (withdrawn): The method of claim 93, wherein co-administration of the polypeptide to
the subject is carried out before introducing said expression cassette.
95. (withdrawn): The method of claim 93, wherein co-administration of the polypeptide to
the subject is carried out concurrently with introducing said expression cassette.
96. (withdrawn): The method of claim 93, wherein co-administration of the polypeptide to
the subject is carried out after introducing said expression cassette.
97. (canceled).